John Fitzgerald

John Fitzgerald

Auto-generated profile, based on publicly available information

John Fitzgerald

Celularity Inc., Florham Park, NJ, United States

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 1996 in Asian Studies Review
Verified
Journal Article
Closed access
JFJohn Fitzgerald
John Fitzgerald
(1996). China's provinces in reform. Asian Studies Review: Vol. 19, No. 3, pp. 139-144.


20 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MGManojkumar Gunasekaran
Manojkumar Gunasekaran
ADAndrea Difiglia
Andrea Difiglia
JFJohn Fitzgerald
John Fitzgerald
RHRobert Hariri
Robert Hariri
WTWilliam van der Touw
William van der Touw
TMTanel Mahlakõiv
Tanel Mahlakõiv
Influenza A virus (IAV) infections are a significant recurrent threat to public health and a significant burden on global economy, highlighting the need for developing more effective therapies. Natural killer (NK) cells play a pivotal role in the control of pulmonary IAV infection, however, little is known about the therapeutic potential of adoptively transferred NK cells for viral infections. Here, we investigated the antiviral activity of CYNK, human placental hematopoietic stem cell-derived NK cells, against IAV infectionin vitro. Virus infection induced the expression of NK cell activating ligands on respiratory epithelial cells, resulting in enhanced recognition by CYNK cells. Upon co-culture with IAV-infected epithelial cells, CYNK exhibited elevated degranulation and increased production of IFN-γ, TNF-α and GM-CSF in a virus dose-dependent manner. Furthermore, CYNK showed virus dose-dependent cytotoxicity against IAV-infected cells. The antiviral activity of CYNK was mediated by NKp46 and NKG2D. Together, these data demonstrate that CYNK possesses potent antiviral function against IAV and warrant clinical investigations for adoptive NK cell therapies against viral infections.